Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
Sponsored by AstraZeneca
About this trial
Last updated 14 years ago
Study ID
5077US/0049
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18 to 65 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 22 years ago
What is this trial about?
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the
treatment of a major depressive episode in patients with bipolar disorder.
What are the participation requirements?
Inclusion Criteria
- Written Informed Consent;
- Bipolar disorder with most recent episode depressed;
- Outpatient status
Exclusion Criteria
- Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening;
- Patients whose current episode of depression exceeds 12 months or is less than 4 weeks